Crinetics Pharmaceuticals, Inc. (CRNX)
A
Pipeline Grade
Financial Position (from SEC Filings)
$115.1M
Cash & Equivalents
$124.7M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$3,879M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PALTUSOTINE HYDROCHLORIDE
PALSONIFY |
APPROVED | Acromegaly, Carcinoid, Carcinoid Intestine Tumor, Carcinoid Syndrome, Carcinoid Syndrome Diarrhea, Carcinoid Tumor, Carcinoid Tumor of Cecum, Carcinoid Tumor of Ileum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia, Cushing Disease, Cushing Syndrome, Ectopic ACTH Syndrome, Healthy Volunteers, Neuroendocrine Neoplasm, Neuroendocrine Tumors, SST2-positive Neuroendocrine Neoplasms |
Upcoming Catalysts
No upcoming catalysts detected for this company.